CERS earnings analysis
What we found in CERS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cerus Corporation's Q1 2026 report reveals a revenue of $59.9 million, exceeding estimates of $51.2 million and an EPS loss of $0.01, surpassing an expected loss of $0.03. The report also includes raised full-year product revenue guidance to $227-$231 million, up from a previous range of $224-$228 million, showing optimism for growth despite ongoing challenges in the regulatory landscape and high operational costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surpassed Expectations
- Q1 2026 revenue was $59.9 million, exceeding estimates of $51.2 million, marking an increase from $48.8 million in Q1 2025.
- EPS Better Than Consensus
- Reported diluted EPS loss was $0.01, better than the consensus estimate of a $0.03 loss.
- Raised Revenue Guidance
- Full-year product revenue guidance increased to $227-$231 million from $224-$228 million.
- Increased Cash Reserves
- Cash and cash equivalents increased to $27.9 million from $20.0 million the prior quarter.
- Decreased Interest Expense
- Interest expense decreased to $1.872 million from $2.110 million in Q1 2025, reflecting a decline in financing costs.
- Growth in Product Revenue
- Product revenue rose to $53.7 million from $43.2 million year-over-year, primarily driven by increased sales volumes.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dependency on BARDA Funding
- Future funding from BARDA is uncertain; if funding is reduced or terminated, it could hinder product development activities.
- Regulatory Approval Risks
- Challenges with the regulatory certification of the red blood cell system could delay commercialization and increase costs.
- Supply Chain Vulnerabilities
- Reliance on sole suppliers for key materials poses risks of disruption; recent market volatility may exacerbate this.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.01
- Segment
- Product revenue: $53.7 million
- Segment
- Government contract revenue: $6.2 million
What they said about what is next.
Full-year 2026 product revenue guidance raised from $224 million - $228 million.
The filing reads better than the one before it.
What came before.
- 10-K · March 2, 2026
- Cerus reports revenue momentum in 2025 with total fiscal-year revenue of $234.0M (Q1 $49M; Q2 $60M; Q3 $60M; Q4 $65M) and stable gross margins (~59.9%). Operating performance improved materially (FY operating margin…
- 10-Q · November 6, 2025
- Cerus reported total revenue of $60.237M in Q3 2025 (product revenue $52.698M; government contract revenue $7.539M), up vs Q3 2024. The company recorded operating income of $1.236M (vs an operating loss of $0.961M a…
- 10-Q · May 1, 2025
- Cerus reported Q1 revenue of $43.239M (product $43.239M; government $5.614M) — up year-over-year but below consensus — with a net loss of $7.718M (EPS -$0.04). Gross profit on product revenue was $25.424M (gross margin…
- 10-K · February 26, 2025
- Cerus describes a focused commercial strategy to expand adoption of its INTERCEPT Blood System for platelets, plasma and cryoprecipitation (commercialized in the U.S. and multiple international markets) while continuing…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CERS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever